{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:36:25Z","timestamp":1776479785077,"version":"3.51.2"},"reference-count":61,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Elevated concentrations of serum uric acid (SUA) are associated\nwith several conditions, including cardiovascular disease. The present study aimed to estimate\nthe impact of statin therapy on SUA levels through a systematic review and meta-analysis of\nclinical trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>PubMed, Embase, Web of Science, and Scopus were searched on January 14, 2022,\nto identify eligible clinical trials. The intervention group received statins as monotherapy or in\ncombination with other drugs, and the control group received non-statins or placebo. Studies\nreporting SUA levels before and after treatment were selected for further analysis. Finally, the\ndata were pooled, and the mean changes in SUA, total cholesterol, high-density lipoprotein\n(HDL), low-density lipoprotein (LDL), and triglycerides were reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Out of 1269 identified studies, 23 were included in the review. A total of 3928 participants\nreceived statin therapy, and 1294 were included in control groups. We found a significant\nreduction in SUA levels following statin therapy (mean difference (MD) = -26.67\n\u03bcmol\/L with 95% confidence interval (CI) [-44.75, -8.60] (P =0.004)). Atorvastatin (MD =\n-37.93 \u03bcmol\/L [-67.71, -8.15]; P &lt; 0.0001), pravastatin (MD = -12.64 \u03bcmol\/L [-18.64, -6.65];\nP &lt; 0.0001), and simvastatin (MD = -5.95 \u03bcmol\/L [-6.14, -5.80]; P &lt; 0.0001), but not rosuvastatin,\nwere significantly associated with a reduction in SUA levels. An analysis comparing different\ntypes of statins showed that pravastatin 20-40 mg\/day could significantly reduce SUA\nwhen compared to simvastatin 10-20 mg\/day (-21.86 \u03bcmol\/L [-36.33,-7.39]; P =0.003).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Statins were significantly associated with a decrease in SUA levels, particularly\natorvastatin, which was found to be most effective in lowering SUA. Atorvastatin may be the\nmost appropriate cholesterol-lowering agent for patients with or at risk of hyperuricemia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230207124516","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:57:35Z","timestamp":1675771055000},"page":"1726-1739","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Effect of Statin Therapy on Serum Uric Acid Levels: A\nSystematic Review and Meta-analysis"],"prefix":"10.2174","volume":"31","author":[{"given":"Abolfazl","family":"Akbari","sequence":"first","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahya","family":"Razmi","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Paramedical Sciences, Mashhad University of Medical Sciences,\nMashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Rafiee","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medicine, Perth, Australia and Lipid Disorders Clinic, Cardiometabolic Services, Royal Perth Hospital, University of Western Australia, Perth, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences,\nMashhad, Iran"},{"name":"School of Medicine, The University of Western Australia, Perth, Australia"},{"name":"Department\nof Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40266-015-0328-z","volume":"32","author":"Deedwania P.C.","year":"2015","unstructured":"Deedwania P.C.; Stone P.H.; Fayyad R.S.; Laskey R.E.; Wilson D.J.; Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: A post hoc analysis of the SAGE trial. Drugs Aging  2015,32(12),1055-1065","journal-title":"Drugs Aging"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","volume":"76","author":"Derosa G.","year":"2016","unstructured":"Derosa G.; Maffioli P.; Reiner &#x17D;.; Simental-Mend&#xED;a L.E.; Sahebkar A.; Impact of statin therapy on plasma uric acid concentrations: A systematic review and meta-analysis. Drugs  2016,76(9),947-956","journal-title":"Drugs"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","volume":"56","author":"Sahebkar A.","year":"2014","unstructured":"Sahebkar A.; Chew G.T.; Watts G.F.; Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res  2014,56(1),47-66","journal-title":"Prog Lipid Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"9902","DOI":"10.1038\/srep09902","volume":"5","author":"Serban C.","year":"2015","unstructured":"Serban C.; Sahebkar A.; Ursoniu S.; Mikhailidis D.P.; Rizzo M.; Lip G.Y.H.; Kees Hovingh G.; Kastelein J.J.P.; Kalinowski L.; Rysz J.; Banach M.; A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep  2015,5(1),9902","journal-title":"Sci Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.5114\/aoms.2019.89330","volume":"17","author":"Sohrevardi S.","year":"2019","unstructured":"Sohrevardi S.; Nasab F.; Mirjalili M.; Bagherniya M.; Tafti A.; Jarrahzadeh M.; Azarpazhooh M.; Saeidmanesh M.; Banach M.; Jamialahmadi T.; Sahebkar A.; Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Arch Med Sci  2019,17(5),1423-1428","journal-title":"Arch Med Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"101024","DOI":"10.1016\/j.arr.2020.101024","volume":"58","author":"Bahrami A.","year":"2020","unstructured":"Bahrami A.; Bo S.; Jamialahmadi T.; Sahebkar A.; Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res Rev  2020,58,101024","journal-title":"Ageing Res Rev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"105986","DOI":"10.1016\/j.phrs.2021.105986","volume":"175","author":"Bland A.R.","year":"2022","unstructured":"Bland A.R.; Payne F.M.; Ashton J.C.; Jamialahmadi T.; Sahebkar A.; The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res  2022,175,105986","journal-title":"Pharmacol Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"101127","DOI":"10.1016\/j.plipres.2021.101127","volume":"84","author":"Sahebkar A.","year":"2021","unstructured":"Sahebkar A.; Kiaie N.; Gorabi A.M.; Mannarino M.R.; Bianconi V.; Jamialahmadi T.; Pirro M.; Banach M.; A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res  2021,84,101127","journal-title":"Prog Lipid Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijge.2018.02.010","volume":"12","author":"Lin C.F.","year":"2018","unstructured":"Lin C.F.; Chang Y.H.; Chien S.C.; Lin Y.H.; Yeh H.Y.; Epidemiology of dyslipidemia in the Asia Pacific Region. Int J Gerontol  2018,12(1),2-6","journal-title":"Int J Gerontol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","volume":"135","author":"Bahrami A.","year":"2018","unstructured":"Bahrami A.; Parsamanesh N.; Atkin S.L.; Banach M.; Sahebkar A.; Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res  2018,135,230-238","journal-title":"Pharmacol Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.5114\/aoms\/141155","volume":"17","author":"Khalifeh M.","year":"2021","unstructured":"Khalifeh M.; Penson P.; Banach M.; Sahebkar A.; Statins as anti-pyroptotic agents. Arch Med Sci  2021,17(5),1414-1417","journal-title":"Arch Med Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","volume":"60","author":"Koushki K.","year":"2021","unstructured":"Koushki K.; Shahbaz S.K.; Mashayekhi K.; Sadeghi M.; Zayeri Z.D.; Taba M.Y.; Banach M.; Al-Rasadi K.; Johnston T.P.; Sahebkar A.; Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol  2021,60(2),175-199","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.5114\/aoms.2020.100304","volume":"16","author":"Shakour N.","year":"2020","unstructured":"Shakour N.; Ruscica M.; Hadizadeh F.; Cirtori C.; Banach M.; Jamialahmadi T.; Sahebkar A.; Statins and C-reactive protein: In silico evidence on direct interaction. Arch Med Sci  2020,16(6),1432-1439","journal-title":"Arch Med Sci"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1160\/TH14-11-0937","volume":"114","author":"Sahebkar A.","year":"2015","unstructured":"Sahebkar A.; Serban C.; Mikhailidis D.P.; Undas A.; Lip G.Y.H.; Muntner P.; Bittner V.; Ray K.K.; Watts G.F.; Hovingh G.K.; Rysz J.; Kastelein J.J.; Banach M.; Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost  2015,114(3),546-557","journal-title":"Thromb Haemost"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1160\/th15-08-0620","volume":"115","author":"Sahebkar A.","year":"2016","unstructured":"Sahebkar A.; Serban C.; Ursoniu S.; Mikhailidis D.P.; Undas A.; Lip G.Y.H.; Bittner V.; Ray K.K.; Watts G.F.; Hovingh G.K.; Rysz J.; Kastelein J.J.P.; Banach M.; The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thromb Haemost  2016,115(3),520-532","journal-title":"Thromb Haemost"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.5114\/aoms.2020.94655","volume":"16","author":"Reiner &#x17D;.","year":"2020","unstructured":"Reiner &#x17D;.; Hatamipour M.; Banach M.; Pirro M.; Al-Rasadi K.; Jamialahmadi T.; Radenkovic D.; Montecucco F.; Sahebkar A.; Statins and the COVID-19 main protease: In silico evidence on direct interaction. Arch Med Sci  2020,16(3),490-496","journal-title":"Arch Med Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms\/149633","volume":"18","author":"Vahedian-Azimi A.","year":"2022","unstructured":"Vahedian-Azimi A.; Mannarino M.; Shojaie S.; Rahimibashar F.; Esmaeili Gouvarchin Galeh H.; Banach M.; Bianconi V.; Pirro M.; Sahebkar A.; Effect of statins on prevalence and mortality of influenza virus infection: A systematic review and meta-analysis. Arch Med Sci  2022,18(6),1-44","journal-title":"Arch Med Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.5114\/aoms\/132950","volume":"17","author":"Vahedian-Azimi A.","year":"2021","unstructured":"Vahedian-Azimi A.; Mohammadi S.; Beni F.; Banach M.; Guest P.; Jamialahmadi T.; Sahebkar A.; Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch Med Sci  2021,17(3),579-595","journal-title":"Arch Med Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11883-020-00837-9","volume":"22","author":"Kouhpeikar H.","year":"2020","unstructured":"Kouhpeikar H.; Delbari Z.; Sathyapalan T.; Simental- Mend&#xED;a L.E.; Jamialahmadi T.; Sahebkar A.; The effect of statins through mast cells in the pathophysiology of atherosclerosis: A review. Curr Atheroscler Rep  2020,22(5),19","journal-title":"Curr Atheroscler Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2174\/1874467214666210210123206","volume":"14","author":"Gorabi A.M.","year":"2021","unstructured":"Gorabi A.M.; Kiaie N.; Bianconi V.; Pirro M.; Jamialahmadi T.; Sahebkar A.; Statins attenuate fibrotic manifestations of cardiac tissue damage. Curr Mol Pharmacol  2021,14(5),782-797","journal-title":"Curr Mol Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11745-010-3517-x","volume":"46","author":"Parizadeh S.M.R.","year":"2011","unstructured":"Parizadeh S.M.R.; Azarpazhooh M.R.; Moohebati M.; Nematy M.; Ghayour-Mobarhan M.; Tavallaie S.; Rahsepar A.A.; Amini M.; Sahebkar A.; Mohammadi M.; Ferns G.A.A.; Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids  2011,46(4),333-340","journal-title":"Lipids"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2018.03.045","volume":"261","author":"Kuwabara M.","year":"2018","unstructured":"Kuwabara M.; Borghi C.; Cicero A.F.G.; Hisatome I.; Niwa K.; Ohno M.; Johnson R.J.; Lanaspa M.A.; Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int J Cardiol  2018,261,183-188","journal-title":"Int J Cardiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/ndt\/gfl538","volume":"22","author":"Athyros V.G.","year":"2006","unstructured":"Athyros V.G.; Mikhailidis D.P.; Liberopoulos E.N.; Kakafika A.I.; Karagiannis A.; Papageorgiou A.A.; Tziomalos K.; Ganotakis E.S.; Elisaf M.; Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Nephrol Dial Transplant  2006,22(1),118-127","journal-title":"Nephrol Dial Transplant"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1074248412444463","volume":"18","author":"Moutzouri E.","year":"2013","unstructured":"Moutzouri E.; Liberopoulos E.N.; Florentin M.; Liamis G.; Elisaf M.S.; Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther  2013,18(1),13-18","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/jgs.13607","volume":"63","author":"Wu C.Y.","year":"2015","unstructured":"Wu C.Y.; Hu H.Y.; Chou Y.J.; Huang N.; Chou Y.C.; Lee M.S.; Li C.P.; High serum uric acid levels are associated with all-cause and cardiovascular, but not cancer, mortality in elderly adults.  J Am Geriatr Soc  2015,63(9),1829-1836","journal-title":"J Am Geriatr Soc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/15257771003741323","volume":"29","author":"Ogata N.","year":"2010","unstructured":"Ogata N.; Fujimori S.; Oka Y.; Kaneko K.; Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids  2010,29(4-6),321-324","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15257770.2012.657763","volume":"31","author":"Nezami N.","year":"2012","unstructured":"Nezami N.; Safa J.; Salari B.; Ghorashi S.; Khosraviani K.; Davari-Farid S.; Hashemi-Aghdam Y.; Nargabad O.N.; Tabrizi J.S.; Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy. Nucleosides Nucleotides Nucleic Acids  2012,31(4),353-363","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"Moher D.","year":"2015","unstructured":"Moher D.; Shamseer L.; Clarke M.; Ghersi D.; Liberati A.; Petticrew M.; Shekelle P.; Stewart L.A.; Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev  2015,4(1),1","journal-title":"Syst Rev"},{"key":"ref=29","author":"Higgins J.P.","year":"2009","unstructured":"Higgins J.P.;  Cochrane handbook for systematic reviews of interventions Version 502  2009","journal-title":"Cochrane handbook for systematic reviews of interventions Version 502"},{"key":"ref=30","first-page":"3","author":"Tufanaru C.","year":"2017","unstructured":"Tufanaru C.; Munn Z.; Aromataris E.; Campbell J.; Hopp L.;  Systematic reviews of effectiveness  2017,3-10","journal-title":"Systematic reviews of effectiveness"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3109\/10641969909070853","volume":"21","author":"Imai Y.","year":"1999","unstructured":"Imai Y.; Suzuki H.; Saito T.; Tsuji I.; Abe K.; Saruta T.; The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Clin Exp Hypertens  1999,21(8),1345-1355","journal-title":"Clin Exp Hypertens"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/j.ajkd.2003.12.023","volume":"43","author":"Athyros V.G.","year":"2004","unstructured":"Athyros V.G.; Elisaf M.; Papageorgiou A.A.; Symeonidis A.N.; Pehlivanidis A.N.; Bouloukos V.I.; Milionis H.J.; Mikhailidis D.P.; Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am J Kidney Dis  2004,43(4),589-599","journal-title":"Am J Kidney Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.metabol.2005.03.010","volume":"54","author":"Athyros V.G.","year":"2005","unstructured":"Athyros V.G.; Mikhailidis D.P.; Papageorgiou A.A.; Didangelos T.P.; Peletidou A.; Kleta D.; Karagiannis A.; Kakafika A.I.; Tziomalos K.; Elisaf M.; Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism  2005,54(8),1065-1074","journal-title":"Metabolism"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.conctc.2015.12.008","volume":"2","author":"Balaguer C.","year":"2016","unstructured":"Balaguer C.; Peralta A.; R&#xED;os &#xC1;.; Iglesias A.; Valera J.L.; Noguera A.; Soriano J.B.; Agust&#xED; &#xC0;.; Sala-Llinas E.; Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. Contemp Clin Trials Commun  2016,2,91-96","journal-title":"Contemp Clin Trials Commun"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/nep.12502","volume":"20","author":"Fassett R.G.","year":"2015","unstructured":"Fassett R.G.; Robertson I.K.; Ball M.J.; Geraghty D.P.; Coombes J.S.; Effects of atorvastatin on oxidative stress in chronic kidney disease. Nephrology (Carlton)  2015,20(10),697-705","journal-title":"Nephrology (Carlton)"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00380-007-1008-7","volume":"23","author":"Ge C.J.","year":"2008","unstructured":"Ge C.J.; Lu S.Z.; Chen Y.D.; Wu X.F.; Hu S.J.; Ji Y.; Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels  2008,23(2),91-95","journal-title":"Heart Vessels"},{"key":"ref=37","first-page":"90","volume":"16","author":"Gleim G.","year":"2009","unstructured":"Gleim G.; Ballantyne C.M.; Liu N.; Thompson-Bell S.; McCrary Sisk C.; Pasternak R.C.; Efficacy and safety profile of coadministered ER niacin\/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol  2009,16(2),90","journal-title":"Br J Cardiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/MCA.0b013e328352ffec","volume":"23","author":"Iwata A.","year":"2012","unstructured":"Iwata A.; Miura S.; Tanaka T.; Ike A.; Sugihara M.; Nishikawa H.; Kawamura A.; Saku K.; Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Coron Artery Dis  2012,23(5),315-321","journal-title":"Coron Artery Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/0091270006292629","volume":"46","author":"Kostapanos M.S.","year":"2006","unstructured":"Kostapanos M.S.; Milionis H.J.; Gazi I.; Kostara C.; Bairaktari E.T.; Elisaf M.; Rosuvastatin increases &#x3B1;-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol  2006,46(11),1337-1343","journal-title":"J Clin Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.pharep.2019.01.014","volume":"71","author":"Krysiak R.","year":"2019","unstructured":"Krysiak R.; Kowalcze K.; Bednarska-Czerwi\u0144ska A.; Okopie\u0144 B.; The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. Pharmacol Rep  2019,71(3),417-421","journal-title":"Pharmacol Rep"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jacl.2013.11.003","volume":"8","author":"Ruscica M.","year":"2014","unstructured":"Ruscica M.; Gomaraschi M.; Mombelli G.; Macchi C.; Bosisio R.; Pazzucconi F.; Pavanello C.; Calabresi L.; Arnoldi A.; Sirtori C.R.; Magni P.; Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol  2014,8(1),61-68","journal-title":"J Clin Lipidol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4111\/icu.2019.60.6.472","volume":"60","author":"Taheri F.","year":"2019","unstructured":"Taheri F.; Taheri M.; Basiri A.; Khoshdel A.; Samadian F.; Tavasoli S.; Effects of short-term atorvastatin use in patients with calcium stones: A randomized placebo-controlled clinical trial. Investig Clin Urol  2019,60(6),472-479","journal-title":"Investig Clin Urol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3109\/03009742.2011.586649","volume":"40","author":"Tam L-S.","year":"2011","unstructured":"Tam L-S.; Li E.K.; Shang Q.; Tomlinson B.; Lee V.W.; Lee K.K.; Li M.; Kuan W.P.; Li T.K.; Tseung L.; Yip G.W.K.; Freedman B.; Yu C-M.; Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand J Rheumatol  2011,40(6),411-421","journal-title":"Scand J Rheumatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.atherosclerosis.2010.11.002","volume":"214","author":"Tousoulis D.","year":"2011","unstructured":"Tousoulis D.; Andreou I.; Tsiatas M.; Miliou A.; Tentolouris C.; Siasos G.; Papageorgiou N.; Papadimitriou C.A.; Dimopoulos M.A.; Stefanadis C.; Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress. Atherosclerosis  2011,214(1),151-157","journal-title":"Atherosclerosis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ahj.2004.04.005","volume":"148","author":"Milionis H.J.","year":"2004","unstructured":"Milionis H.J.; Kakafika A.I.; Tsouli S.G.; Athyros V.G.; Bairaktari E.T.; Seferiadis K.I.; Elisaf M.S.; Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J  2004,148(4),635-640","journal-title":"Am Heart J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1185\/030079906X112462","volume":"22","author":"Milionis H.J.","year":"2006","unstructured":"Milionis H.J.; Rizos E.; Kostapanos M.; Filippatos T.D.; Gazi I.F.; Ganotakis E.S.; Goudevenos J.; Mikhailidis D.P.; Elisaf M.S.; Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin  2006,22(6),1123-1131","journal-title":"Curr Med Res Opin"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1253\/circj.CJ-10-1281","volume":"75","author":"Saku K.","year":"2011","unstructured":"Saku K.; Zhang B.; Noda K.; Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (Quantity and Quality of LDL)-The patrol trial. Circ J  2011,75(6),1493-505","journal-title":"Circ J"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1253\/circj.CJ-15-1379","volume":"80","author":"Matsushita K","year":"2016","unstructured":"Matsushita K; Hibi K; Komura N; Akiyama E; Maejima N; Iwahashi N; Effects of 4 statins on regression of coronary plaque in acute coronary syndrome. Circulat J  2016,80(7),1634-43","journal-title":"Circulat J"},{"key":"ref=49","first-page":"493","volume":"6","author":"Khan M.","year":"2014","unstructured":"Khan M.; Murti K.; Grover V.; Lal K.; Singh D.; Das P.; Atorvastatin vs. rosuvastatin; fenofibrate as an add on: an exploratory study. Int J Pharm Pharm Sci  2014,6,493-498","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/0091270003255920","volume":"43","author":"Milionis H.J.","year":"2003","unstructured":"Milionis H.J.; Papakostas J.; Kakafika A.; Chasiotis G.; Seferiadis K.; Elisaf M.S.; Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol  2003,43(8),825-830","journal-title":"J Clin Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/biof.5520180213","volume":"18","author":"Passi S.","year":"2003","unstructured":"Passi S.; Stancato A.; Aleo E.; Dmitrieva A.; Littarru G.P.; Statins lower plasma and lymphocyte ubiquinol\/ubiquinone without affecting other antioxidants and PUFA. Biofactors  2003,18(1-4),113-124","journal-title":"Biofactors"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"8745","DOI":"10.3390\/ijms21228745","volume":"21","author":"Murphy C.","year":"2020","unstructured":"Murphy C.; Deplazes E.; Cranfield C.G.; Garcia A.; The role of structure and biophysical properties in the pleiotropic effects of statins. Int J Mol Sci  2020,21(22),8745","journal-title":"Int J Mol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/jama.1993.03510030078038","volume":"270","author":"Cappuccio F.P.","year":"1993","unstructured":"Cappuccio F.P.; Strazzullo P.; Farinaro E.; Trevisan M.; Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA  1993,270(3),354-359","journal-title":"JAMA"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1159\/000492590","volume":"43","author":"Li F.","year":"2018","unstructured":"Li F.; Guo H.; Zou J.; Chen W.; Lu Y.; Zhang X.; Fu C.; Xiao J.; Ye Z.; The association of urinary sodium and potassium with renal uric acid excretion in patients with chronic kidney disease. Kidney Blood Press Res  2018,43(4),1310-1321","journal-title":"Kidney Blood Press Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1073\/pnas.0901249106","volume":"106","author":"Woodward O.M.","year":"2009","unstructured":"Woodward O.M.; K&#xF6;ttgen A.; Coresh J.; Boerwinkle E.; Guggino W.B.; K&#xF6;ttgen M.; Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA  2009,106(25),10338-10342","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/aps.2009.85","volume":"30","author":"Rodrigues A.C.","year":"2009","unstructured":"Rodrigues A.C.; Curi R.; Genvigir F.D.V.; Hirata M.H.; Hirata R.D.C.; The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol Sin  2009,30(7),956-964","journal-title":"Acta Pharmacol Sin"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12872-019-1026-2","volume":"19","author":"Ali N.","year":"2019","unstructured":"Ali N.; Rahman S.; Islam S.; Haque T.; Molla N.H.; Sumon A.H.; Kathak R.R.; Asaduzzaman M.; Islam F.; Mohanto N.C.; Hasnat M.A.; Nurunnabi S.M.; Ahmed S.; The relationship between serum uric acid and lipid profile in Bangladeshi adults. BMC Cardiovasc Disord  2019,19(1),42","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"Choi H.K.","year":"2005","unstructured":"Choi H.K.; Mount D.B.; Reginato A.M.; Pathogenesis of gout. Ann Intern Med  2005,143(7),499-516","journal-title":"Ann Intern Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.12669\/pjms.36.6.2945","volume":"36","author":"Zhang Z.","year":"2020","unstructured":"Zhang Z.; Xu M.; Wei F.; Shang L.; Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis. Pak J Med Sci  2020,36(6),1334-1338","journal-title":"Pak J Med Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.semarthrit.2018.03.007","volume":"48","author":"Keller S.F.","year":"2018","unstructured":"Keller S.F.; Rai S.K.; Lu N.; Oza A.; Jorge A.M.; Zhang Y.; Choi H.K.; Statin use and mortality in gout: A general population-based cohort study. Semin Arthritis Rheum  2018,48(3),449-455","journal-title":"Semin Arthritis Rheum"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3892\/etm.2014.2027","volume":"8","author":"Xilifu D.","year":"2014","unstructured":"Xilifu D.; Abudula A.; Rehemu N.; Zhao L.; Zhou X.; Zhang X.; Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction. Exp Ther Med  2014,8(6),1683-1688","journal-title":"Exp Ther Med"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230207124516","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213499\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230207124516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T17:09:22Z","timestamp":1713373762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213499\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":61,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230207124516","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}